1 |
Gobira PH, LaMar J, Marques J, Sartim A, Silveira K, Santos L, Wegener G, Guimaraes FS, Mackie K, Lu HC, Joca S. CB1 Receptor Silencing Attenuates Ketamine-Induced Hyperlocomotion Without Compromising Its Antidepressant-Like Effects. Cannabis Cannabinoid Res 2022. [PMID: 36067014 DOI: 10.1089/can.2022.0072] [Reference Citation Analysis]
|
2 |
Sharafi A, Pakkhesal S, Fakhari A, Khajehnasiri N, Ahmadalipour A. Rapid treatments for depression: Endocannabinoid system as a therapeutic target. Neurosci Biobehav Rev 2022;137:104635. [PMID: 35351488 DOI: 10.1016/j.neubiorev.2022.104635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
3 |
Calapai F, Cardia L, Calapai G, Di Mauro D, Trimarchi F, Ammendolia I, Mannucci C. Effects of Cannabidiol on Locomotor Activity. Life 2022;12:652. [DOI: 10.3390/life12050652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
4 |
Poulia N, Delis F, Brakatselos C, Ntoulas G, Asprogerakas MZ, Antoniou K. CBD Effects on Motor Profile and Neurobiological Indices Related to Glutamatergic Function Induced by Repeated Ketamine Pre-Administration. Front Pharmacol 2021;12:746935. [PMID: 34776964 DOI: 10.3389/fphar.2021.746935] [Reference Citation Analysis]
|